Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PROC Stock Forecast 2025-2026
$0.15
Current Price
$16.92M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PROC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PROC Price Momentum
0.0%
1 Week Change
+400.0%
1 Month Change
-93.3%
1 Year Change
-93.6%
Year-to-Date Change
-96.0%
From 52W High of $3.78
+1,400.0%
From 52W Low of $0.01
📊 TOP ANALYST CALLS
Did PROC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Procaps is one of their latest high-conviction picks.
Latest PROC Stock Price Targets & Analyst Predictions
PROC has shown a year-to-date change of -93.6% and a 1-year change of -93.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PROC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PROC Analyst Ratings
0
Buy
1
Hold
0
Sell
PROC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.15
Latest PROC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PROC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 6, 2023 | Brookline Capital | Kemp Dolliver | Hold | Downgrade | $4.50 |
Procaps Group S.A. (PROC) Competitors
The following stocks are similar to Procaps based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Procaps Group S.A. (PROC) Financial Data
Procaps Group S.A. has a market capitalization of $16.92M with a P/E ratio of 1.5x. The company generates $409.92M in trailing twelve-month revenue with a 58.4% profit margin.
Revenue growth is +7.6% quarter-over-quarter, while maintaining an operating margin of +19.1% and return on equity of -2,265.2%.
Valuation Metrics
Market Cap
$16.92M
Enterprise Value
$259.86M
P/E Ratio
1.5x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
+7.6%
Gross Margin
+57.8%
Operating Margin
+19.1%
Net Margin
+58.4%
EPS Growth
+7.3%
Financial Health
Cash/Price Ratio
+114.3%
Current Ratio
1.5x
Debt/Equity
7.5x
ROE
-2,265.2%
ROA
+9.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Procaps Group S.A. (PROC) Business Model
About Procaps Group S.A.
What They Do
Pharmaceutical company specializing in innovative health products.
Business Model
Procaps Group generates revenue by developing, manufacturing, and commercializing a diverse range of pharmaceutical and nutritional products, including prescription medications and supplements. The company's emphasis on research and development, along with its advanced softgel technology, allows it to create unique dosage forms that meet a variety of health needs across over 50 countries.
Additional Information
The company is recognized as a pioneer in the Latin American pharmaceutical market and emphasizes strategic partnerships and supply chain efficiencies to enhance its global reach. Procaps Group plays a crucial role in disease prevention and management, contributing to improved health outcomes in the sectors it serves.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
5,000
CEO
Mr. Ruben Minski
Country
Luxembourg
IPO Year
2019
Website
www.procapsgroup.comProcaps Group S.A. (PROC) Latest News & Analysis
Latest News
Procaps Group Receives Delisting Notice From Nasdaq
10 months ago
Quick Summary
Procaps Group, S.A. (NASDAQ: PROC) will be delisted from Nasdaq due to non-compliance with listing rules. Shares will begin trading on the OTC Markets starting February 4, 2025.
Why It Matters
Procaps' delisting from Nasdaq due to non-compliance with financial reporting raises concerns about its financial health and transparency, potentially impacting investor confidence and share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nasdaq will remove Procaps Group for not meeting financial reporting standards, effective February 4, highlighting compliance challenges for businesses.
Why It Matters
The removal of Procaps from Nasdaq highlights compliance risks, potentially affecting investor confidence in similar companies and signaling increased scrutiny in financial reporting standards.
Source: Invezz
Market Sentiment:
Negative
Procaps Group Receives Additional Delinquency Letter
11 months ago
Quick Summary
Procaps Group, S.A. (NASDAQ: PROC) has received notice from Nasdaq regarding a filing delinquency for its interim financial statements for the period ending June 30, 2024.
Why It Matters
Procaps Group's filing delinquency may signal financial instability, raising concerns over compliance and governance, potentially impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
11 months ago
Quick Summary
Procaps Group announced key changes following its recent Shareholders and Board of Directors meetings, including new Board composition, restructured committees, and updates to executive leadership.
Why It Matters
Changes in Procaps Group's board and executive leadership may signal strategic shifts, impacting company direction and investor confidence, potentially affecting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Procaps Group, S.A. (NASDAQ: PROC) announced strategic transactions and governance updates to enhance its financial position and support long-term growth.
Why It Matters
Procaps' strategic transactions and governance updates may enhance its financial stability and growth prospects, potentially increasing investor confidence and share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
1 year ago
Quick Summary
Procaps Group (NASDAQ: PROC) has been notified by Nasdaq of potential delisting due to its failure to file the Form 20-F for 2023. The company can request a hearing to contest this action.
Why It Matters
Procaps Group’s failure to file required financial documents risks delisting from Nasdaq, potentially impacting share liquidity and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PROC Stock
What is Procaps Group S.A.'s (PROC) stock forecast for 2026?
Analyst forecasts for Procaps Group S.A. (PROC) are not currently available. The stock is trading at $0.15.
Is PROC stock a good investment in 2026?
According to current analyst ratings, PROC has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PROC stock?
Price predictions from Wall Street analysts for PROC are not currently available. The stock is trading at $0.15.
What is Procaps Group S.A.'s business model?
Procaps Group generates revenue by developing, manufacturing, and commercializing a diverse range of pharmaceutical and nutritional products, including prescription medications and supplements. The company's emphasis on research and development, along with its advanced softgel technology, allows it to create unique dosage forms that meet a variety of health needs across over 50 countries.
What is the highest forecasted price for PROC Procaps Group S.A.?
Price targets from Wall Street analysts for PROC are not currently available. The stock is trading at $0.15.
What is the lowest forecasted price for PROC Procaps Group S.A.?
Price targets from Wall Street analysts for PROC are not currently available. The stock is trading at $0.15.
What is the overall PROC consensus from analysts for Procaps Group S.A.?
The overall analyst consensus for PROC is neutral. Out of 1 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are PROC stock price projections?
Stock price projections, including those for Procaps Group S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 7:19 PM UTC